AR085302A1 - Metodo de produccion de anticuerpos sialilados - Google Patents

Metodo de produccion de anticuerpos sialilados

Info

Publication number
AR085302A1
AR085302A1 ARP120100573A ARP120100573A AR085302A1 AR 085302 A1 AR085302 A1 AR 085302A1 AR P120100573 A ARP120100573 A AR P120100573A AR P120100573 A ARP120100573 A AR P120100573A AR 085302 A1 AR085302 A1 AR 085302A1
Authority
AR
Argentina
Prior art keywords
antibody
domain
expressing
stirated
antibodies
Prior art date
Application number
ARP120100573A
Other languages
English (en)
Spanish (es)
Inventor
Beatrice Cameron
Bruno Genet
Fabienne Soubrier
Francis Blanche
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR085302A1 publication Critical patent/AR085302A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP120100573A 2011-02-24 2012-02-22 Metodo de produccion de anticuerpos sialilados AR085302A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305200 2011-02-24
EP11306090 2011-09-01

Publications (1)

Publication Number Publication Date
AR085302A1 true AR085302A1 (es) 2013-09-18

Family

ID=45774189

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100573A AR085302A1 (es) 2011-02-24 2012-02-22 Metodo de produccion de anticuerpos sialilados

Country Status (6)

Country Link
US (1) US20140046032A1 (enExample)
EP (1) EP2678357A1 (enExample)
JP (1) JP2014508759A (enExample)
AR (1) AR085302A1 (enExample)
TW (1) TW201241182A (enExample)
WO (1) WO2012113863A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2014018747A2 (en) 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9580511B2 (en) * 2013-03-11 2017-02-28 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
EP2991666B1 (en) * 2013-05-02 2020-03-25 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
CA2908407C (en) 2013-05-29 2022-06-14 F. Hoffmann-La Roche Ag Quantitative control of sialylation
CA2911965C (en) 2013-07-05 2018-06-19 F. Hoffmann-La Roche Ag Process for the mono- and bi-sialylation of glycoproteins employing n-terminally truncated beta-galactoside alpha-2,6-sialyltransferase mutants
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
HUE061339T2 (hu) 2014-03-19 2023-06-28 Genzyme Corp Targetáló csoportok helyspecifikus glikotechnikai átalakítása
AU2015293949B2 (en) 2014-07-21 2019-07-25 Teknologian Tutkimuskeskus Vtt Oy Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
JP2018500934A (ja) 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
EP3037527A1 (en) * 2014-12-22 2016-06-29 F. Hoffmann-La Roche AG Sialyltransferase without CMP-dependent sialidase activity
EP3544612A4 (en) 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
EP3354278A1 (en) * 2017-01-31 2018-08-01 Sanofi Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
FR3080376B1 (fr) * 2018-04-20 2022-12-09 Lab Francais Du Fractionnement Autoanticorps hautement sialyles et leurs utilisations
JP7575401B2 (ja) 2019-04-03 2024-10-29 ジェンザイム・コーポレーション 断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
AU2022388727A1 (en) * 2021-11-09 2024-05-16 Amgen Inc. Production of therapeutic proteins
AU2024333211A1 (en) 2023-08-30 2026-03-19 Astellas Pharma Inc. Fc REGION VARIANT
WO2025101901A1 (en) * 2023-11-10 2025-05-15 The Board Of Trustees Of The Leland Stanford Junior University Use of sialylated ivig or igg fc region-containing protein for preventing or treating respiratory virus diseases

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US20020045207A1 (en) * 1997-10-31 2002-04-18 Lynne A. Krummen Glycoprotein production process
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
EP1427828B1 (en) 2001-09-14 2010-04-28 Cellectis Random integration of a polynucleotide after in vivo linearization
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
CN101506238B (zh) * 2005-06-30 2013-11-06 森托科尔公司 具有提高治疗活性的方法和成分
DK1945665T3 (da) 2005-10-21 2012-02-06 Genzyme Corp Antistof-baserede terapimidler med forhøjet ADCC-aktivitet
WO2008057634A2 (en) 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
NZ568012A (en) 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
EP2195023B1 (en) 2007-08-29 2018-03-07 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
AU2008311366B2 (en) 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JP2011500059A (ja) 2007-10-15 2011-01-06 セントコア・オーソ・バイオテツク・インコーポレーテツド ヒト抗アミロイド抗体、組成物、方法及び使用
EP2597155B1 (en) 2007-10-25 2016-11-23 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
WO2009054537A1 (ja) 2007-10-25 2009-04-30 Kagoshima University アミロイドβペプチドのミミック分子を用いたペプチドワクチン
CN104098695B (zh) 2007-10-29 2018-09-07 道健康生活医药株式会社 抗体及其应用
AU2008322523B2 (en) 2007-11-16 2013-10-10 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
CA2707859A1 (en) 2007-12-11 2009-06-18 Glaxo Group Limited Antigen binding proteins specific against beta amyloid
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering

Also Published As

Publication number Publication date
WO2012113863A1 (en) 2012-08-30
US20140046032A1 (en) 2014-02-13
JP2014508759A (ja) 2014-04-10
EP2678357A1 (en) 2014-01-01
TW201241182A (en) 2012-10-16

Similar Documents

Publication Publication Date Title
MX389743B (es) Proceso mejorado para la producción de oligosacáridos fucosilados.
BR112015031233A2 (pt) métodos de produção de derivados de ácidos graxos omega-hidroxilados
NZ630568A (en) Methods and means for the production of ch3 domain-comprising molecules
ZA201703241B (en) Anti-c5 antibodies and methods of use
BR112016010340A2 (pt) novos métodos para se produzir tert ativa
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
BR112017021255A2 (pt) microrganismo modificado para a produção otimizada de 2,4-di-hidroxibutirato
MX2013014937A (es) Cultivo de celulas de mamifero.
MX353581B (es) Procesos para producir productos de fermentacion.
WO2015028324A3 (en) A method for producing modified resveratrol
UA110946C2 (uk) Спосіб одержання лігніну
MX2013008903A (es) Metodos de desarrollo de variantes de terpeno sintasa.
BR112014026308A2 (pt) composições de cultura celular e métodos para produção de polipeptídeos
WO2011100477A3 (en) Antibodies and processes for preparing the same
MX2015012168A (es) Expansión de celulas madre adultas in vitro.
WO2013041969A3 (en) Didemnin biosynthetic gene cluster in tistrella mobilis
EP4446338A3 (en) Cells and method of cell culture
WO2011009058A3 (en) Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
MX342235B (es) Metodo optimizado para captura de anticuerpo por cromatografia de modo mixto.
BR112015022529A2 (pt) meios de cultura de células e processos de produção de anticorpo
MX2019007411A (es) Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
BR112021024852A2 (pt) Métodos de cultura de célula e composições para produção de anticorpo
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.
WO2015100160A3 (en) Transgenic production of heparin
WO2013162905A8 (en) Methods of producing and using regulatory b-cells

Legal Events

Date Code Title Description
FB Suspension of granting procedure